Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression

• Published in: PloS one Vol. 6; no. 5; p. e19530
• Main Authors: Browne, Andrew W, Leddon, Jennifer L, Currier, Mark A, Williams, Jon P, Frischer, Jason S, Collins, Margaret H, Ahn, Chong H, Cripe, Timothy P
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 11.05.2011; Public Library of Science (PLoS)
• Subjects: Animals; Base Sequence; Biomarkers; Biomarkers, Tumor - metabolism; Cancer; Cancer genetics; Cancer screening; Children & youth; Computer engineering; Cytotoxicity; DNA Primers; Engineering; Expression vectors; Fluorescent Antibody Technique; Gaussia; Gene expression; Gene transfer; Genes; Genetic Vectors; Health risks; Hematology; Herpes simplex; Herpes viruses; Humans; Immunoassay; Intravenous administration; Keratinocytes; Medical screening; Medicine; Mice; Mutation; Neoplasms - diagnosis; Neoplasms - pathology; Oncology; Oncolysis; Pediatrics; Prostate cancer; Replication; Risk groups; Simplexvirus - genetics; Toxicity; Tumors; Urine; Virus replication; Viruses; Warts; United States > US; Ohio
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0019530

Cancer biomarkers facilitate screening and early detection but are known for only a few cancer types. We demonstrated the principle of inducing tumors to secrete a serum biomarker using a systemically administered gene delivery vector that targets tumors for selective expression of an engineered cassette. We exploited tumor-selective replication of a conditionally replicative Herpes simplex virus (HSV) combined with a replication-dependent late viral promoter to achieve tumor-selective biomarker expression as an example gene delivery vector. Virus replication, cytotoxicity and biomarker production were low in quiescent normal human foreskin keratinocytes and high in cancer cells in vitro. Following intravenous injection of virus >90% of tumor-bearing mice exhibited higher levels of biomarker than non-tumor-bearing mice and upon necropsy, we detected virus exclusively in tumors. Our strategy of forcing tumors to secrete a serum biomarker could be useful for cancer screening in high-risk patients, and possibly for monitoring response to therapy. In addition, because oncolytic vectors for tumor specific gene delivery are cytotoxic, they may supplement our screening strategy as a "theragnostic" agent. The cancer screening approach presented in this work introduces a paradigm shift in the utility of gene delivery which we foresee being improved by alternative vectors targeting gene delivery and expression to tumors. Refining this approach will usher a new era for clinical cancer screening that may be implemented in the developed and undeveloped world.